News Briefs

The FDA’s Oncologic Drugs Advisory Committee voted to keep most indications for a handful of immune checkpoint inhibitors that target programmed death-1/programmed death ligand-1 (PD-1/PD-L1) and received accelerated approval pending further clinical trial data (RSP 4/21, p. 1). Receiving “yes” votes were Tecentriq (atezolizumab) from Roche subsidiary Genentech USA, Inc. for certain triple-negative breast cancers and urothelial carcinomas and Merck & Co., Inc.’s Keytruda (pembrolizumab) for certain urothelial carcinomas and hepatocellular carcinomas. Keytruda received a negative vote for certain gastric cancers and Bristol Myers Squibb’s Opdivo (nivolumab) did also for certain hepatocellular carcinomas. View the meeting materials at https://bit.ly/3uj4XqJ.

Amber Specialty Pharmacy is partnering with MarkeTouch Media to enhance communication with patients via automated, targeted and responsive outbound notifications across services through the TouchPoint Management solution. The move frees up staff from performing routine tasks, allowing them to focus on patients, says the company. Visit www.amberpharmacy.com.

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/Specialty_article_Anthem_Launches_Voluntary.jpg
September 9

Anthem Launches Voluntary Oncology Dose Reduction Program

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/Specialty_Pharmacy_article_Home_Infusion_Policies.jpg
September 9

Legislation Seeks to Change Medicare Home Infusion Policies

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/Specialty_Pharmacy_article_Specialty_Trend.jpg
September 9

Specialty Trend Increase Slows; Biosimilars Are Having Impact

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today